Cell line · CVCL_1714
Papers50
1 to 20 of 50
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Uncovering a role for METTL13 in malignant transformation of human hematopoietic stem cells and in the progression of pediatric leukemia. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Incorporation of genome-bound cellular proteins into HIV-1 particles regulates viral infection. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dimerization-dependent NOTCH receptor transactivation unveils a class of highly selective NOTCH signalling inhibitors. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Uncovering a role for METTL13 in malignant transformation of human hematopoietic stem cells and in the progression of pediatric leukemia. | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40909497 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. | Sci Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Intron-oriented HTLV-1 integration in an adult T-cell leukemia/lymphoma cell line sustains expression of intact ift81 mRNA. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. | Cell Chem Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors. | Cancer Immunol Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| GFI1 Cooperates with IKZF1/IKAROS to Activate Gene Expression in T-cell Acute Lymphoblastic Leukemia. | Mol Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. | Theranostics | 2021 | Its Methods give the RRID and name the line | PubMed | |
| HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. | Cell Host Microbe | 2021 | Its Methods give the RRID and name the line | PubMed | |
| HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1714/papers